Abbott Laboratories came in Wednesday with a "solid ... Abbott stock undercut its 200-day line on the first-quarter report. Follow Allison Gatlin on X, the platform formerly known as Twitter ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products ...

Abbott Laboratories, the world's largest maker of heart stents and adult nutritional beverages, is doubling down on the crowded $6.2 billion U.S. snack market with a line of six bars that it hopes ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

In the second quarter, Abbott Laboratories' sales grew 4% year over year to $10.4 billion. The company's top line increased 9.3% organically if we exclude the effect of its coronavirus diagnostic ...

Abbott Laboratories' (NYSE:ABT) stock up by 8.7% over the past three months. Since the market usually pay for a... We recently compiled a list of the Jim Cramer’s Top 10 Stock Picks You Can’t ...